|
|
 Previous Article | Table of Contents | Next Article 
Hydroxyurea-induced augmentation of fetal hemoglobin production in patients
with sickle cell anemia
S Charache, GJ Dover, MA Moyer and JW Moore
Five patients with sickle cell anemia were treated with hydroxyurea (HU),
in hopes of augmenting their production of fetal hemoglobin. Laboratory
responses in two patients treated for more than 2 years were encouraging
and there were suggestions of clinical improvement. Long- term HU therapy
should be considered for severely affected adults with sickle cell anemia
who are willing to accept what is probably a small risk of carcinogenesis.
Preliminary chromosomal analysis and knowledge of the clastogenic
properties of HU suggest that conception and pregnancy should be avoided.
Pharmacokinetic studies will probably be necessary to adjust individual
dosage schedules so that cytotoxicity is avoided. F cell responses can be
seen in 2 to 3 weeks if the HU dose is optimal, but establishment of a
large number of F cells in the circulation may take a month or longer.
Volume 69,
Issue 1,
pp. 109-116,
01/01/1987
Copyright © 1987 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. M. Dykxhoorn, L. D. Schlehuber, I. M. London, and J. Lieberman
Determinants of specific RNA interference-mediated silencing of human beta-globin alleles differing by a single nucleotide polymorphism
PNAS,
April 11, 2006;
103(15):
5953 - 5958.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bank
Regulation of human fetal hemoglobin: new players, new complexities
Blood,
January 15, 2006;
107(2):
435 - 443.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Weinberg, X. Ji, M. Sutton, S. Perrine, Y. Galperin, Q. Li, S. A. Liebhaber, G. Stamatoyannopoulos, and G. F. Atweh
Butyrate increases the efficiency of translation of {gamma}-globin mRNA
Blood,
February 15, 2005;
105(4):
1807 - 1809.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. F. Atweh, J. DeSimone, Y. Saunthararajah, H. Fathallah, R. S. Weinberg, R. L. Nagel, M. E. Fabry, and R. J. Adams
Hemoglobinopathies
Hematology,
January 1, 2003;
2003(1):
14 - 39.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. S. Pace, G. L. White, G. J. Dover, M. S. Boosalis, D. V. Faller, and S. P. Perrine
Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo
Blood,
December 15, 2002;
100(13):
4640 - 4648.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Vadolas, H. Wardan, M. Orford, L. Voullaire, F. Zaibak, R. Williamson, and P. A. Ioannou
Development of sensitive fluorescent assays for embryonic and fetal hemoglobin inducers using the human beta -globin locus in erythropoietic cells
Blood,
December 1, 2002;
100(12):
4209 - 4216.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Ware, B. Eggleston, R. Redding-Lallinger, W. C. Wang, K. Smith-Whitley, C. Daeschner, B. Gee, L. A. Styles, R. W. Helms, T. R. Kinney, et al.
Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy
Blood,
January 1, 2002;
99(1):
10 - 14.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. F. Bunn
Induction of Fetal Hemoglobin in Sickle Cell Disease
Blood,
March 15, 1999;
93(6):
1787 - 1789.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. F. Atweh, M. Sutton, I. Nassif, V. Boosalis, G. J. Dover, S. Wallenstein, E. Wright, L. McMahon, G. Stamatoyannopoulos, D. V. Faller, et al.
Sustained Induction of Fetal Hemoglobin by Pulse Butyrate Therapy in Sickle Cell Disease
Blood,
March 15, 1999;
93(6):
1790 - 1797.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. G. Engstrom and E. Lofvenberg
Treatment of Myeloproliferative Disorders With Hydroxyurea: Effects on Red Blood Cell Geometry and Deformability
Blood,
May 15, 1998;
91(10):
3986 - 3991.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. I. Rodriguez, J. G. Kuhn, G. R. Weiss, S. G. Hilsenbeck, J. R. Eckardt, A. Thurman, D. A. Rinaldi, S. Hodges, D. D. Von Hoff, and E. K. Rowinsky
A Bioavailability and Pharmacokinetic Study of Oral and Intravenous Hydroxyurea
Blood,
March 1, 1998;
91(5):
1533 - 1541.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. F. Bunn
Pathogenesis and Treatment of Sickle Cell Disease
N. Engl. J. Med.,
September 11, 1997;
337(11):
762 - 769.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Adams-Graves, A. Kedar, M. Koshy, M. Steinberg, R. Veith, D. Ward, R. Crawford, S. Edwards, J. Bustrack, and M. Emanuele
RheothRx (Poloxamer 188) Injection for the Acute Painful Episode of Sickle Cell Disease: A Pilot Study
Blood,
September 1, 1997;
90(5):
2041 - 2046.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Steinberg, Z.-H. Lu, F. B. Barton, M. L. Terrin, S. Charache, G. J. Dover, and the Multicenter Study of Hydroxyurea
Fetal Hemoglobin in Sickle Cell Anemia: Determinants of Response to Hydroxyurea
Blood,
February 1, 1997;
89(3):
1078 - 1088.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. D. Sher, G. D. Ginder, J. Little, S. Yang, G. J. Dover, and N. F. Olivieri
Extended Therapy with Intravenous Arginine Butyrate in Patients with {beta}-Hemoglobinopathies
N. Engl. J. Med.,
June 15, 1995;
332(24):
1606 - 1610.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Perrine, G. D. Ginder, D. V. Faller, G. H. Dover, T. Ikuta, H. E. Witkowska, S.-p. Cai, E. P. Vichinsky, and N. F. Olivieri
A Short-Term Trial of Butyrate to Stimulate Fetal-Globin-Gene Expression in the {beta}-Globin Disorders
N. Engl. J. Med.,
January 14, 1993;
328(2):
81 - 86.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
H. F. Bunn
Reversing Ontogeny
N. Engl. J. Med.,
January 14, 1993;
328(2):
129 - 131.
[Full Text]
|
|
|
|
|
